We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis (SEPTOX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04819360
Recruitment Status : Recruiting
First Posted : March 26, 2021
Last Update Posted : February 21, 2022
Sponsor:
Collaborator:
Centre Hospitalier Universitaire Vaudois
Information provided by (Responsible Party):
Brigitte Schürch, Centre Hospitalier Universitaire Vaudois

Brief Summary:

Botulinum toxin type A injections into the detrusor at a dose of 200 units (U) of BOTOX® are a recognized second-line treatment for the treatment of adult neurogenic lower urinary tract disorders. Anticholinergics are established as the usual first-line treatment for neurogenic detrusor hyperactivity, but are oft not sufficiently effective and have significant side effects. In patients with multiple sclerosis (MS) suffering from overactive bladder, the 200 U dose of BOTOX® is very effective but induces a risk of urinary retention in 30% of patients requiring the temporary use of self-catheterization1. At 100 U, a recent study shows the efficacy and very good tolerance of botulinum toxin A in terms of probing risk in MS patients with overactive bladder and failure of anticholinergics. Furthermore, the efficacy of anticholinergics in MS has been little studied and is also disputed.

The investigators plan to test the therapeutic alternative as the first line of treatment in two groups of randomized MS patients from a homogeneous population suffering from overactive bladder:

  • a group testing the effectiveness of low doses of botulinum toxin type A (100 U, BOTOX®),
  • the other group receiving the standard anticholinergic treatment (solifenacin succinate, Vesicare®).

During this pilot study, the efficacy and side effects profile of each treatment will be analyzed in order to determine the amplitudes of effect and the safety profiles in this population and in order to establish the statistical hypotheses for a subsequent randomized multicenter study. The aim of this study will be to establish the benefit of botulinum toxin at a dose of 100 U as a first-line treatment instead of anticholinergics


Condition or disease Intervention/treatment Phase
Urinary Bladder, Neurogenic Multiple Sclerosis Drug: VESIcare 10Mg Tablet Drug: Botox 100 UNT Injection Phase 4

Detailed Description:

Botulinum toxin type A (BOTOX®) injections will performed on an outpatient basis by cystoscopy under local anesthesia. Twenty minutes after an intravesical instillation of 20 ml of 0.2% ropivacaine, the botulinum toxin is injected into the detrusor muscle using a flexible injection needle at a rate of 10 U of BOTOX® per mL (10 points of 1 mL injections). Intravenous prophylaxis (cefuroxime 1.5 g) will be performed 30 minutes before the injections.

Patients in the Vesicare® arm will be given the tablets at the baseline visit to be taken once a day in the morning for 12 weeks. For this arm, there will be no antibiotic prophylaxis.

Randomization will be carried out via eCRF in the secuTrial® environment with an integrated Interactive Web Response System (IWRS) function allowing the allocation of a participant to one of the two intervention groups. Randomization will be carried out using a randomization table in blocks of 2, predefined without the knowledge of the investigator, respecting a balanced allocation between the two groups, necessary given the modest number of participants in the study.

The intensity of therapeutic responses for each treatment is not precisely known in this patient population. As a result, there are no reliable preliminary data which would allow the investigators to calculate under these "effect size" assumptions the necessary numbers of participants to be randomized between the two intervention groups in order to demonstrate a possible superiority of treatment by injection of BOTOX® 100 U in comparison to the reference anticholinergic treatment. The comparative study will therefore only be accessible after determining the intensity of these effects.

Within the framework of a pilot study not directly comparative of the therapeutic approaches but seeking to identify the amplitude of the effects obtained independently by the two treatments, it does not appear necessary to resort to a study design with "double-dummy" to leave the patient blind to the method used. Such an approach would require the use of a sham injection by cystoscopic route in the group treated with anticholinergics and would not appear ethical in this context.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Injections of Botulinum Toxin A or Anticholinergic Treatment as First Line Therapy to Treat Neurogenic Overactive Bladder in Patients With Multiple Sclerosis
Actual Study Start Date : June 1, 2021
Estimated Primary Completion Date : November 30, 2022
Estimated Study Completion Date : January 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Vesicare
Group 1: will be treated with an anticholinergic (Vesicare® 10 mg per day for 12 weeks)
Drug: VESIcare 10Mg Tablet

Vesicare® 10 mg per day for 12 weeks

Vesicare 10mg 12 weeks

Other Name: Vesicare

Active Comparator: Botox
Group 2: will receive an intra-detrusor injection of a low dose of botulinum toxin type A (100 U of BOTOX®).
Drug: Botox 100 UNT Injection
1 injection of Botox® 100 UNT
Other Name: Botox




Primary Outcome Measures :
  1. Magnitude of effect - Number of micturitions per 24h [ Time Frame: 6 weeks ]
    The difference in mean values of [the number of micturitions / 24 h for the last 3 days] at T0 (inclusion) and T6W (6 weeks after start of the treatment).


Secondary Outcome Measures :
  1. Other parameters of effects - Number of urgent urinations per 24h [ Time Frame: 2, 6 and 12 weeks after treatment start ]

    The difference in mean values of [the number of episodes of urgent urination / 24 h for the last 3 days] at T0 (inclusion) and T2W (2 weeks after start of the treatment).

    The difference in mean values of [the number of episodes of urgent urination / 24 h for the last 3 days] at T0 (inclusion) and T6W (6 weeks after start of the treatment).

    The difference in mean values of [the number of episodes of urgent urination / 24 h for the last 3 days] at T0 (inclusion) and T12W (12 weeks after start of the treatment).


  2. Other parameters of effects - Number of urgency urinary incontinence episodes per 24h [ Time Frame: 2, 6 and 12 weeks after treatment start ]

    The difference in mean values of [the number of urgency urinary incontinence episodes / 24 h for the last 3 days] at T0 (inclusion) and T2W (2 weeks after start of the treatment).

    The difference in mean values of [the number of urgency urinary incontinence episodes / 24 h for the last 3 days] at T0 (inclusion) and T6W (6 weeks after start of the treatment).

    The difference in mean values of [the number of urgency urinary incontinence episodes / 24 h for the last 3 days] at T0 (inclusion) and T12W (12 weeks after start of the treatment).


  3. Other parameters of effects - Number of nocturnal micturition episodes per 24h [ Time Frame: 2, 6 and 12 weeks after treatment start ]

    The difference in mean values of [the number of nocturnal micturition episodes / 24 h for the last 3 days] at T0 (inclusion) and T2W (2 weeks after start of the treatment).

    The difference in mean values of [the number of nocturnal micturition episodes / 24 h for the last 3 days] at T0 (inclusion) and T6W (6 weeks after start of the treatment).

    The difference in mean values of [the number of nocturnal micturition episodes / 24 h for the last 3 days] at T0 (inclusion) and T12W (12 weeks after start of the treatment).


  4. Other parameters of effects - Number of 100% dry patients [ Time Frame: 6 and 12 weeks after treatment start ]

    The difference in mean values of [the number of 100% dry patients / 24 h for the last 3 days] at T0 (inclusion) and T6W (6 weeks after start of the treatment).

    The difference in mean values of [the number of 100% dry patients / 24 h for the last 3 days] at T0 (inclusion) and T12W (12 weeks after start of the treatment).


  5. Other parameters of effects - Urodynamic parameter : cystomanometric capacity [ Time Frame: 6 weeks after treatment start ]
    The difference in cystomanometric capacity at 6 weeks after the start of the treatment, as compared to inclusion values.

  6. Other parameters of effects - Urodynamic parameter : reflex volume at first contraction [ Time Frame: 6 weeks after treatment start ]
    The difference in reflex volume at first contraction at 6 weeks after the start of the treatment, as compared to inclusion values.

  7. Other parameters of effects - Urodynamic parameter : bladder compliance [ Time Frame: 6 weeks after treatment start ]

    Bladder compliance describes the relationship between change in bladder volume (ΔV) and change in detrusor pressure (Δpdet).

    Compliance is calculated by dividing the volume change (∆V) by the change in detrusor pressure (∆pdet) during that change in bladder volume (C= ΔV/∆pdet). It is expressed in ml/cm H2O.


  8. Other parameters of effects - Urodynamic parameter : maximum detrusor pressure [ Time Frame: 6 weeks after treatment start ]
    The difference in maximum detrusor pressure at 6 weeks after the start of the treatment, as compared to inclusion values.

  9. Other parameters of effects - Urodynamic parameter : post-void residual after flowmetry [ Time Frame: 6 weeks after treatment start ]
    The difference in post-void residual after flowmetry at 6 weeks after the start of the treatment, as compared to inclusion values.


Other Outcome Measures:
  1. Patients reported outcomes - Patients' satisfaction [ Time Frame: 2, 6 and 12 weeks ]
    Patients' satisfaction, measured by the Patient Global Impression of Improvement (PGI-I), at 2, 6 and 12 weeks after the start of the treatment, as compared to inclusion values.

  2. Patients reported outcomes - Patients' specific quality of life [ Time Frame: 2, 6 and 12 weeks ]
    Patients' specific quality of life, measured by the Urinary Incontinence Quality of Life Scale (I-QOL), at 2, 6 and 12 weeks after the start of the treatment, as compared to inclusion values.

  3. Patients reported outcomes - Subjective improvement [ Time Frame: 2, 6 and 12 weeks ]
    Patients' subjective improvement, measured by a Visual Analog Scale (VAS), at 2, 6 and 12 weeks after the start of the treatment, as compared to inclusion values.

  4. Security - Self-catheterizations [ Time Frame: Any time during the 12 weeks of the trial ]
    Need for self-catheterizations according to pre-specified criteria, at any time during the trial

  5. Security - Urinary tract infections [ Time Frame: Any time during the 12 weeks of the trial ]
    Number of urinary tract infections episodes, at any time during the trial

  6. Security - Adverse drug reactions due to anticholinergic drugs [ Time Frame: Any time during the 12 weeks of the trial ]
    Number of adverse drug reactions due to anticholinergic drugs, at any time during the trial

  7. Security - Adverse drug reactions due to Botox [ Time Frame: Any time during the 12 weeks of the trial ]
    Number of adverse drug reactions due to Botox, at any time during the trial



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with multiple sclerosis (MS) with neurogenic detrusor overactivity proven by urodynamics
  • Stable MS with an Expanded Disability Severity Score (EDSS) less than or equal to 6.5
  • Voluntary micturitions
  • Number of micturitions > 8 per day, with or without episodes of urgency and urgency incontinence
  • Signed informed consent form

Exclusion Criteria:

  • Pregnancy, breastfeeding
  • Patients requiring self-catheterizations
  • Patients unable or unwilling to learn self-catheterisation
  • Recent (<12 weeks) or current treatment with botulinum toxin for any non-urological indication
  • Recent (≤ 8 weeks) or current treatment with anticholinergic drugs
  • Patients with a positive history or evidence of pelvic / urological abnormality (interstitial cystitis, bladder lithiasis in the 6 months preceding the screening, or any other condition / operation affecting the bladder or prostate)
  • Any contraindication to Vesicare®:

    • Hypersensitivity to the active ingredient or to one of the excipients
    • Urinary retention
    • Untreated narrow-angle glaucoma
    • Severe gastrointestinal illness (e.g. toxic megacolon)
    • Myasthenia gravis
    • Severe hepatic failure
    • Hemodialysis
    • Severe renal failure, or liver function disturbances of moderate severity with concomitant treatment with a strong inhibitor of the CYP3A4 isoenzyme, including patients at risk for these diseases.
  • Any contraindication to BOTOX®:

    • Known hypersensitivity to the active substance or to one of the excipients
    • Presence of a symptomatic infection at the planned injection site(s)
    • Urinary tract infection at the time of planned treatment
    • Patients who present with acute urinary retention at the time of treatment and who do not regularly use bladder catheterization
    • Patients who do not want and / or cannot, if necessary, perform self-intermittent catheterisation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04819360


Contacts
Layout table for location contacts
Contact: Brigitte Schürch, Prof. +41795565677 brigitte.schurch@chuv.ch

Locations
Layout table for location information
Switzerland
Centre Hospitalier Universitaire Vaudois Recruiting
Lausanne, Switzerland, 1011
Contact: Brigitte Schürch, Prof.MD    +41795565677    brigitte.schurch@chuv.ch   
Sub-Investigator: Nuno Grilo, MD         
Sub-Investigator: Marie Theaudin, MD         
Sub-Investigator: Helena Favre, MD         
Sponsors and Collaborators
Brigitte Schürch
Centre Hospitalier Universitaire Vaudois
Investigators
Layout table for investigator information
Principal Investigator: Brigitte Schürch, Prof. Centre Hospitalier Universitaire Vaudois
Publications of Results:
Layout table for additonal information
Responsible Party: Brigitte Schürch, Professor, Centre Hospitalier Universitaire Vaudois
ClinicalTrials.gov Identifier: NCT04819360    
Other Study ID Numbers: SEPTOX
First Posted: March 26, 2021    Key Record Dates
Last Update Posted: February 21, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Brigitte Schürch, Centre Hospitalier Universitaire Vaudois:
Botulinum toxin
Neurogenic bladder
Multiple sclerosis
Anticholinergic drugs
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Urinary Bladder, Neurogenic
Urinary Bladder, Overactive
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Neurologic Manifestations
Solifenacin Succinate
Botulinum Toxins, Type A
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Muscarinic Antagonists
Cholinergic Antagonists
Urological Agents